JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Twist Bioscience Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

34.13 7.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32

Max

34.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

60M

20M

Pardavimai

3.3M

96M

Pelno marža

21.227

Darbuotojai

923

EBITDA

22M

-24M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+22.34% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

166M

2B

Ankstesnė atidarymo kaina

26.74

Ankstesnė uždarymo kaina

34.13

Naujienos nuotaikos

By Acuity

50%

50%

163 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Twist Bioscience Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-23 23:51; UTC

Rinkos pokalbiai

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025-10-23 23:37; UTC

Rinkos pokalbiai

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025-10-23 22:58; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-10-23 22:57; UTC

Rinkos pokalbiai

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -2-

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025-10-23 22:17; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025-10-23 21:41; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025-10-23 21:05; UTC

Uždarbis

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-23 20:35; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025-10-23 20:28; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025-10-23 20:15; UTC

Rinkos pokalbiai
Uždarbis

Global Commodities Roundup: Market Talk

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Adj EPS $1.71

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Sales $5.52B

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q EPS $1.67

2025-10-23 20:09; UTC

Uždarbis

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025-10-23 20:07; UTC

Uždarbis

Blackstone Looks to IPOs for Investment Exits -- Update

2025-10-23 20:05; UTC

Uždarbis

Intel 3Q Gross Margin 38.2% >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025-10-23 20:04; UTC

Uždarbis

Intel: 4Q Guidance Excludes Altera >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Sees 4Q Adj EPS 8c >INTC

Akcijų palyginimas

Kainos pokytis

Twist Bioscience Corp Prognozė

Kainos tikslas

By TipRanks

22.34% į viršų

12 mėnesių prognozė

Vidutinis 38 USD  22.34%

Aukščiausias 50 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Twist Bioscience Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

6

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

31.56 / 38.6884Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

163 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat